Thymoproteasome-Expressing Mesenchymal Stromal Cells Confer Protective Anti-Tumor Immunity via Cross-Priming of Endogenous Dendritic Cells

dc.contributor.authorBikorimana, Jean Pierre
dc.contributor.authorEl Hachem, Nehme
dc.contributor.authorEl-Kadiry, Abed Hakim
dc.contributor.authorAbusarah, Jamilah
dc.contributor.authorSalame, Natasha
dc.contributor.authorShammaa, Riam
dc.contributor.authorRafei, Moutih
dc.contributor.departmentSpecialized Clinical Programs and Services
dc.contributor.departmentGenomics Institute of Precision Medicine
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T12:20:38Z
dc.date.available2025-01-24T12:20:38Z
dc.date.issued2021
dc.description.abstractProteasomes are complex macromolecular structures existing in various forms to regulate a myriad of cellular processes. Besides degrading unwanted or misfolded proteins (proteostasis), distinct immune functions were ascribed for the immunoproteasome and thymoproteasome (TPr) complexes. For instance, antigen degradation during ongoing immune responses mainly relies on immunoproteasome activity, whereas intrathymic CD8 T-cell development requires peptide generation by the TPr complex. Despite these substantial differences, the functional contribution of the TPr to peripheral T-cell immunity remains ill-defined. We herein explored whether the use of mesenchymal stromal cells (MSCs) engineered to exhibit altered proteasomal activity through de novo expression of the TPr complex can be exploited as a novel anti-cancer vaccine capable of triggering potent CD8 T-cell activation. Phenotypic and molecular characterization of MSC-TPr revealed a substantial decrease in MHCI (H2-Kb and H2-Dd) expression along with elevated secretion of various chemokines (CCL2, CCL9, CXCL1, LIX, and CX3CL1). In parallel, transcriptomic analysis pinpointed the limited ability of MSC-TPr to present endogenous antigens, which is consistent with their low expression levels of the peptide-loading proteins TAP, CALR, and PDAI3. Nevertheless, MSC-TPr cross-presented peptides derived from captured soluble proteins. When tested for their protective capacity, MSC-TPr triggered modest anti-tumoral responses despite efficient generation of effector memory CD4 and CD8 T cells. In contrast, clodronate administration prior to vaccination dramatically enhanced the MSC-TPr-induced anti-tumoral immunity clearly highlighting a refractory role mediated by phagocytic cells. Thus, our data elute to a DC cross-priming-dependant pathway in mediating the therapeutic effect of MSC-TPr. © Copyright © 2021 Bikorimana, El-Hachem, El-Kadiry, Abusarah, Salame, Shammaa and Rafei.
dc.identifier.doihttps://doi.org/10.3389/fimmu.2020.596303
dc.identifier.eid2-s2.0-85100448070
dc.identifier.pmid33542714
dc.identifier.urihttp://hdl.handle.net/10938/34352
dc.language.isoen
dc.publisherFrontiers Media S.A.
dc.relation.ispartofFrontiers in Immunology
dc.sourceScopus
dc.subjectAntigen cross-presentation
dc.subjectCancer vaccine
dc.subjectClodronate
dc.subjectCross-priming
dc.subjectEfferocytosis
dc.subjectMesenchymal stromal cell
dc.subjectThymoproteasome
dc.subjectAnimals
dc.subjectAntigen presentation
dc.subjectAntigens, neoplasm
dc.subjectCell line, tumor
dc.subjectCytokines
dc.subjectDendritic cells
dc.subjectEpitope mapping
dc.subjectFemale
dc.subjectGenetic engineering
dc.subjectHumans
dc.subjectImmunomodulation
dc.subjectMesenchymal stem cells
dc.subjectMice
dc.subjectModels, biological
dc.subjectNeoplasms
dc.subjectProteasome endopeptidase complex
dc.subject5' nucleotidase
dc.subjectAccutase
dc.subjectAlexa fluor
dc.subjectCalreticulin
dc.subjectCd4 antigen
dc.subjectCd47 antigen
dc.subjectCd8 antigen
dc.subjectCd86 antigen
dc.subjectCell lytic
dc.subjectChemokine
dc.subjectClodronic acid
dc.subjectCxcl1 chemokine
dc.subjectCytokine
dc.subjectEndoglin
dc.subjectEpithelial derived neutrophil activating factor 78
dc.subjectFractalkine
dc.subjectGamma interferon
dc.subjectGreen fluorescent protein
dc.subjectHermes antigen
dc.subjectImmunoglobulin g
dc.subjectInterleukin 10
dc.subjectInterleukin 1beta
dc.subjectInterleukin 2
dc.subjectL selectin
dc.subjectLipopolysaccharide
dc.subjectLiposome
dc.subjectMonocyte chemotactic protein 1
dc.subjectOvalbumin
dc.subjectPhosphatidylserine
dc.subjectPlatelet endothelial cell adhesion molecule 1
dc.subjectProteasome
dc.subjectReceptor type tyrosine protein phosphatase c
dc.subjectToll like receptor 4
dc.subjectVasculotropin
dc.subjectTumor antigen
dc.subjectAdaptive immunity
dc.subjectAnimal cell
dc.subjectAnimal experiment
dc.subjectAnimal model
dc.subjectAnimal tissue
dc.subjectAnti tumor immunity
dc.subjectAntigen presenting cell
dc.subjectAntineoplastic activity
dc.subjectApoptosis
dc.subjectArticle
dc.subjectBagg albino mouse
dc.subjectBioinformatics
dc.subjectC57bl 6 mouse
dc.subjectCastration resistant prostate cancer
dc.subjectCd4+ t lymphocyte
dc.subjectCd8+ t lymphocyte
dc.subjectCell activation
dc.subjectCell isolation
dc.subjectCell maturation
dc.subjectCell proliferation
dc.subjectCellular immunity
dc.subjectCoculture
dc.subjectComputer language
dc.subjectControlled study
dc.subjectCross presentation
dc.subjectDendritic cell
dc.subjectDown regulation
dc.subjectEnzyme activity
dc.subjectEnzyme linked immunosorbent assay
dc.subjectFlow cytometry
dc.subjectGene expression
dc.subjectGene silencing
dc.subjectGenetic transfection
dc.subjectImmune response
dc.subjectImmunization
dc.subjectImmunoblotting
dc.subjectImmunoproteasome
dc.subjectImmunosuppressive treatment
dc.subjectMacrophage
dc.subjectMesenchymal stroma cell
dc.subjectMicroarray analysis
dc.subjectMouse
dc.subjectNatural killer cell
dc.subjectNonhuman
dc.subjectNucleosome
dc.subjectPhagocyte
dc.subjectPhenotype
dc.subjectProtein expression
dc.subjectProtein homeostasis
dc.subjectProtein phosphorylation
dc.subjectRna extraction
dc.subjectRna sequence
dc.subjectSignal transduction
dc.subjectStroma cell
dc.subjectT cell lymphoma
dc.subjectT lymphocyte activation
dc.subjectThymoma
dc.subjectTumor growth
dc.subjectTumor immunity
dc.subjectUbiquitination
dc.subjectUltracentrifugation
dc.subjectUpregulation
dc.subjectVaccination
dc.subjectVaccine immunogenicity
dc.subjectWestern blotting
dc.subjectAnimal
dc.subjectBiological model
dc.subjectHuman
dc.subjectImmunology
dc.subjectMesenchymal stem cell
dc.subjectMetabolism
dc.subjectNeoplasm
dc.subjectPathology
dc.subjectTumor cell line
dc.titleThymoproteasome-Expressing Mesenchymal Stromal Cells Confer Protective Anti-Tumor Immunity via Cross-Priming of Endogenous Dendritic Cells
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2021-2746.pdf
Size:
2.6 MB
Format:
Adobe Portable Document Format